<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>326</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15147575</PubmedId>
            <Abstract>An ideal prophylactic vaccine against human papillomaviruses (HPV) would be one that can induce broadly reactive antibody titres to at least the major oncogenic strains of HPV. It has been previously shown that HPV structural proteins are highly immunogenic but fail to elicit cross-reactive immune responses against heterologous strains of HPV. Recent studies have demonstrated that the immunity induced by virus-like particles is mostly type specific. In the present study, we determined the breadth of reactivity of antibodies induced in mice immunized with hypervariable epitope constructs (HECs), which represent sequence variants of immunodominant B-cell epitopes of the major capsid protein L1 of HPV. In order to test the breadth of reactivity, sera from immunized mice were tested against peptides representing analogous sequences of HPV types 16, 18, 31 and 45. Mice immunized with HECs based on two epitopes mounted antibody responses that cross-reacted with two different analogues, 16 and 18. Significantly, antibodies from mice immunized with HECs also inhibited haemagglutination mediated by HPV-16 L1 VLPs, suggesting that immunization resulted in the development of antibodies that could bind to viral capsid proteins in their native conformation. Our observations suggest that HECs may overcome the restriction of type specific immunity against HPV.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>321-7</ArticlePages>
            <ArticleTitle>Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Reddy</LastName>
                    <ForeName>K Jyotsna</ForeName>
                </Author>
                <Author>
                    <LastName>Banapour</LastName>
                    <ForeName>Babak</ForeName>
                </Author>
                <Author>
                    <LastName>Anderson</LastName>
                    <ForeName>David E</ForeName>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sang H</ForeName>
                </Author>
                <Author>
                    <LastName>Marquez</LastName>
                    <ForeName>Juan P</ForeName>
                </Author>
                <Author>
                    <LastName>Carlos</LastName>
                    <ForeName>Maria P</ForeName>
                </Author>
                <Author>
                    <LastName>Torres</LastName>
                    <ForeName>Jose V</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Antigens, Viral;Capsid Proteins;Complementarity Determining Regions;Epitopes, B-Lymphocyte;Oncogene Proteins, Viral;Peptide Fragments;Viral Vaccines;L1 protein, Human papillomavirus type 16</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Viral(biosynthesis; immunology); Antibody Specificity; Antigens, Viral(immunology); Capsid Proteins; Complementarity Determining Regions(immunology); Cross Reactions(immunology); Epitopes, B-Lymphocyte(immunology); Erythrocytes(immunology); Female; Hemagglutination(immunology); Humans; Immunization(methods); Mice; Oncogene Proteins, Viral(immunology); Papillomaviridae(classification; immunology); Peptide Fragments(immunology); Viral Vaccines(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>112</Volume>
                <Issue>2</Issue>
                <Title>Immunology</Title>
                <Issn>0019-2805</Issn>
                <MedlineTa>Immunology</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HPV16 L1 (12-31)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGTVGENVPDDLYIKGSGST</LinearSequence>
                        <StartingPosition>12</StartingPosition>
                        <EndingPosition>31</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAM29174.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>333760</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111098</EpitopeId>
                <ReferenceStartingPosition>264</ReferenceStartingPosition>
                <ReferenceEndingPosition>283</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 2a</LocationOfData>
                        <BCellId>1656448</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>AGTVGETVPDDLYIKGSGST</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 6E or 6D, 50% 11D or 11T, t5% of 17S or 25% 17N,  75% of 18G or 25% 18T, and 75% 19S or 25 19R.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>83.3</ResponseFrequency>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-A (aa 264–283), recognized the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGTVGENVPDDLYIKGSGST</LinearSequence>
                                        <StartingPosition>12</StartingPosition>
                                        <EndingPosition>31</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAM29174.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>333760</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-18 L1(325-344)  A. 18</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGTMGDTVPQSLYIKGTGMR</LinearSequence>
                        <StartingPosition>325</StartingPosition>
                        <EndingPosition>344</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABP99807.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>333761</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111097</EpitopeId>
                <ReferenceStartingPosition>264</ReferenceStartingPosition>
                <ReferenceEndingPosition>283</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 2a</LocationOfData>
                        <BCellId>1657691</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>AGTVGETVPDDLYIKGSGST</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 6E or 6D, 50% 11D or 11T, t5% of 17S or 25% 17N,  75% of 18G or 25% 18T, and 75% 19S or 25 19R.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>60</ResponseFrequency>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-A (aa 264–283), recognized the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGTMGDTVPQSLYIKGTGMR</LinearSequence>
                                        <StartingPosition>325</StartingPosition>
                                        <EndingPosition>344</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABP99807.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>333761</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-16 L1 (495-519) B.16</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LLQAGLKAKPKFTLGKRKATPTTSS</LinearSequence>
                        <StartingPosition>495</StartingPosition>
                        <EndingPosition>519</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ACG75893.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>333760</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111493</EpitopeId>
                <ReferenceStartingPosition>469</ReferenceStartingPosition>
                <ReferenceEndingPosition>493</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 2a</LocationOfData>
                        <BCellId>1657692</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LLQAGLRRKPTITPRKRSATPTTSS</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-B (aa 469–493)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 11T or 11K, 50% of 12I or 12 F, 50% of 13T or 13K, 50% of 14P or 14L, and 33% of 18S, 18P, or 18K.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-A (aa 264–283), recognized the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LLQAGLKAKPKFTLGKRKATPTTSS</LinearSequence>
                                        <StartingPosition>495</StartingPosition>
                                        <EndingPosition>519</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ACG75893.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>333760</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-18 L1 (531-555) B.18</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LVQAGLRRKPTIGPRKRSAPSATTS</LinearSequence>
                        <StartingPosition>531</StartingPosition>
                        <EndingPosition>555</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABP99807.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>333761</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111527</EpitopeId>
                <ReferenceStartingPosition>469</ReferenceStartingPosition>
                <ReferenceEndingPosition>493</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 2a</LocationOfData>
                        <BCellId>1657693</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LLQAGLRRKPTITPRKRSATPTTSS</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 11T or 11K, 50% of 12I or 12 F, 50% of 13T or 13K, 50% of 14P or 14L, and 33% of 18S, 18P, or 18K.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>20</ResponseFrequency>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-A (aa 264–283), recognized the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LVQAGLRRKPTIGPRKRSAPSATTS</LinearSequence>
                                        <StartingPosition>531</StartingPosition>
                                        <EndingPosition>555</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABP99807.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>333761</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-31 L1 (265-284) A.31</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGTVGESVPTDLYIKGSGST</LinearSequence>
                        <StartingPosition>265</StartingPosition>
                        <EndingPosition>284</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P17388.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10585</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111775</EpitopeId>
                <ReferenceStartingPosition>264</ReferenceStartingPosition>
                <ReferenceEndingPosition>283</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 324</LocationOfData>
                        <BCellId>1657694</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>AGTVGETVPDDLYIKGSGST</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 6E or 6D, 50% 11D or 11T, t5% of 17S or 25% 17N,  75% of 18G or 25% 18T, and 75% 19S or 25 19R.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-A (aa 264–283), did not recognize the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGTVGESVPTDLYIKGSGST</LinearSequence>
                                        <StartingPosition>265</StartingPosition>
                                        <EndingPosition>284</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P17388.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10585</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-45 L1 (291-312) A.45</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGVMGDTVPTDLYIKGTSANMR</LinearSequence>
                        <StartingPosition>291</StartingPosition>
                        <EndingPosition>312</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABP99903.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10593</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111099</EpitopeId>
                <ReferenceStartingPosition>264</ReferenceStartingPosition>
                <ReferenceEndingPosition>283</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 324</LocationOfData>
                        <BCellId>1657695</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>AGTVGETVPDDLYIKGSGST</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 6E or 6D, 50% 11D or 11T, t5% of 17S or 25% 17N,  75% of 18G or 25% 18T, and 75% 19S or 25 19R.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-A (aa 264–283), did not recognize the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGVMGDTVPTDLYIKGTSANMR</LinearSequence>
                                        <StartingPosition>291</StartingPosition>
                                        <EndingPosition>312</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABP99903.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10593</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-31 L1 (470-494) B.31</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LLQAGYRARPKFKAGKRSAPSASTT</LinearSequence>
                        <StartingPosition>470</StartingPosition>
                        <EndingPosition>494</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P17388.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10585</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111494</EpitopeId>
                <ReferenceStartingPosition>469</ReferenceStartingPosition>
                <ReferenceEndingPosition>493</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 2a</LocationOfData>
                        <BCellId>1657696</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LLQAGLRRKPTITPRKRSATPTTSS</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 11T or 11K, 50% of 12I or 12 F, 50% of 13T or 13K, 50% of 14P or 14L, and 33% of 18S, 18P, or 18K.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-B (aa469-493), did not recognize the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LLQAGYRARPKFKAGKRSAPSASTT</LinearSequence>
                                        <StartingPosition>470</StartingPosition>
                                        <EndingPosition>494</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P17388.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10585</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HPV-45 L1 (499-523) B.45</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LVQAGLRRRPTIGPRKRPAASTSTA</LinearSequence>
                        <StartingPosition>499</StartingPosition>
                        <EndingPosition>523</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABP99903.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10593</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>111528</EpitopeId>
                <ReferenceStartingPosition>469</ReferenceStartingPosition>
                <ReferenceEndingPosition>493</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 2a</LocationOfData>
                        <BCellId>1657697</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000629</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LLQAGLRRKPTITPRKRSATPTTSS</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HEC-A (aa 264–283)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 doses of 100ug, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The animals were immunized with epitopes of the hypervariable regions of HPV major capsid protein L1 in a mixture of peptides.  The mixture of peptides contained 50% of 11T or 11K, 50% of 12I or 12 F, 50% of 13T or 13K, 50% of 14P or 14L, and 33% of 18S, 18P, or 18K.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Sera from mice immunized with hypervariable epitope constructs, HEC-B (aa469-493), did not recognize the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LVQAGLRRRPTIGPRKRPAASTSTA</LinearSequence>
                                        <StartingPosition>499</StartingPosition>
                                        <EndingPosition>523</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABP99903.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10593</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

